A Study of Alectinib (CH5424802/RO5424802) in Participants With Anaplastic Lymphoma Kinase (ALK)-Rearranged Non-Small Cell Lung Cancer (NSCLC)
Public ClinicalTrials.gov record NCT01871805. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase I/II Study of the ALK Inhibitor CH5424802/ RO5424802 in Patients With ALK-Rearranged Non-Small Cell Lung Cancer Previously Treated With Crizotinib
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
This non-randomized, open-label, multicenter study will evaluate the safety and efficacy of alectinib in participants with ALK-rearranged non-small cell lung cancer who failed crizotinib treatment. In Phase I, cohorts of participants will receive escalating doses of alectinib orally twice daily. In Phase II, patients who failed crizotinib treatment will receive the recommended phase II dose.
Study identification
- NCT ID
- NCT01871805
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 1, Phase 2
- Enrollment
- 134 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Sep 30, 2013 (Actual)
- Primary completion
- Oct 24, 2014 (Actual)
- Completion
- Aug 31, 2017 (Actual)
- Last update posted
- Aug 21, 2018
2013 – 2017
United States locations
- U.S. sites
- 39
- U.S. states
- 19
- U.S. cities
- 35
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| University of Alabama at Birmingham | Birmingham | Alabama | 35233 | — |
| University of California Irvine | Irvine | California | 92697 | — |
| UCSD Moores Cancer Center | La Jolla | California | 92093 | — |
| Loma Linda Cancer Center | Loma Linda | California | 92354 | — |
| UCLA | Los Angeles | California | 90095 | — |
| Univ of Colorado Canc Ctr | Aurora | Colorado | 80045 | — |
| National Jewish Health | Denver | Colorado | 80206 | — |
| Lynn Regional Cancer Center West | Boca Raton | Florida | 33486 | — |
| Florida Hospital Cancer Inst | Orlando | Florida | 32804 | — |
| UF Health Orlando | Orlando | Florida | 32806 | — |
| H. Lee Moffitt Cancer Center and Research Inst. | Tampa | Florida | 33612 | — |
| University of Illinois Cancer Center | Chicago | Illinois | 60612 | — |
| Monroe Medical Associates; Ingalls Memorial Hosp | Harvey | Illinois | 60426 | — |
| Massachussets General Hospital | Boston | Massachusetts | 02114 | — |
| Beth Israel Deaconess Medical Center | Boston | Massachusetts | 02215 | — |
| Dana Farber Can Ins | Boston | Massachusetts | 02215 | — |
| Newton-Wellesley Hospital | Newton | Massachusetts | 02462 | — |
| St. Joseph Mercy Hospital; Cancer Care Center. | Ann Arbor | Michigan | 48106 | — |
| Wayne State Uni ; Karmanos Cancer Center | Detroit | Michigan | 48201 | — |
| Hackensack Univ Med Ctr | Hackensack | New Jersey | 07601 | — |
| Roswell Park Cancer Inst. | Buffalo | New York | 14263 | — |
| Memorial Sloan-Kettering Cancer Center | Commack | New York | 11725 | — |
| Richmond University Medical Center; Pharmacy Department | Staten Island | New York | 10310 | — |
| Wake Forest University Health Sciences | Winston-Salem | North Carolina | 27157 | — |
| Gabrail Cancer Center | Canton | Ohio | 44718 | — |
| The Ohio State University Comprehensive Cancer Center | Columbus | Ohio | 43210 | — |
| Providence Portland Med Ctr | Portland | Oregon | 97213 | — |
| Oregon Health & Science Uni | Portland | Oregon | 97239 | — |
| St. Luke's Hospital; Pharmacy Department | Bethlehem | Pennsylvania | 18015 | — |
| Penn State Hershey Cancer Institute | Hershey | Pennsylvania | 17033 | — |
| Fox Chase Cancer Center | Philadelphia | Pennsylvania | 19111 | — |
| University of Pittsburgh Cancer Pavillion | Pittsburgh | Pennsylvania | 15232 | — |
| MUSC Hollings Cancer Center | Charleston | South Carolina | 29425 | — |
| Center for Biomedical Research LLC | Knoxville | Tennessee | 37909 | — |
| Texas Oncology-Baylor Sammons Cancer Center | Dallas | Texas | 75246 | — |
| MD Anderson Cancer Center | Houston | Texas | 77030 | — |
| Virginia Cancer Specialists, PC | Fairfax | Virginia | 22031 | — |
| Swedish Cancer Inst. | Seattle | Washington | 98104 | — |
| University of Wisconsin | Madison | Wisconsin | 53792 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 3 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT01871805, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Aug 21, 2018 · Synced Oct 18, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT01871805 live on ClinicalTrials.gov.